De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Atea Pharmaceuticals Beheer
Beheer criteriumcontroles 2/4
De CEO Atea Pharmaceuticals' is Jean-Pierre Sommadossi, benoemd in Jul2012, heeft een ambtstermijn van 12.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.93M, bestaande uit 11.5% salaris en 88.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 7.09% van de aandelen van het bedrijf, ter waarde $ 20.04M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 5.1 jaar.
Belangrijke informatie
Jean-Pierre Sommadossi
Algemeen directeur
US$5.9m
Totale compensatie
| Percentage CEO-salaris | 11.5% |
| Dienstverband CEO | 12.3yrs |
| Eigendom CEO | 7.1% |
| Management gemiddelde ambtstermijn | 4.2yrs |
| Gemiddelde ambtstermijn bestuur | 5.1yrs |
Recente managementupdates
Recent updates
Atea wins FDA Fast Track status for dengue treatment
Sep 26Atea Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
May 13
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Jan 05Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
Nov 25A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Oct 20U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs
Jun 17Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 15Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
May 13Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Apr 08Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
Mar 06Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares
Jan 30
Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$164m |
| Dec 31 2023 | US$6m | US$683k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$131m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$6m | US$650k | -US$116m |
| Sep 30 2022 | n/a | n/a | US$36m |
| Jun 30 2022 | n/a | n/a | US$16m |
| Mar 31 2022 | n/a | n/a | US$48m |
| Dec 31 2021 | US$34m | US$650k | US$121m |
| Sep 30 2021 | n/a | n/a | US$25m |
| Jun 30 2021 | n/a | n/a | US$35m |
| Mar 31 2021 | n/a | n/a | US$24m |
| Dec 31 2020 | US$3m | US$437k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$811k | US$400k | -US$14m |
Compensatie versus markt: De totale vergoeding ($USD 5.93M ) Jean-Pierre } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 1.46M ).
Compensatie versus inkomsten: De vergoeding van Jean-Pierre is gestegen terwijl het bedrijf verliesgevend is.
CEO
Jean-Pierre Sommadossi (68 yo)
12.3yrs
Tenure
US$5,925,790
Compensatie
Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 12.3yrs | US$5.93m | 7.09% $ 19.9m | |
| CFO, Executive VP of Legal & Secretary | 10.8yrs | US$1.96m | 0.79% $ 2.2m | |
| Executive VP of Finance & Chief Accounting Officer | 2.8yrs | US$1.52m | 0.025% $ 69.5k | |
| Chief Development Officer | 4.2yrs | US$2.11m | 0.042% $ 117.8k | |
| Chief Medical Officer | 4.2yrs | US$1.85m | 0.030% $ 85.5k | |
| Senior Vice President of Investor Relations & Corporate Communications | 3.8yrs | geen gegevens | geen gegevens | |
| Vice President of Marketing | 2.8yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Chemistry | no data | geen gegevens | geen gegevens | |
| Executive Vice President of Early Stage Development | no data | geen gegevens | geen gegevens | |
| Chief Commercial Officer | 6yrs | US$1.52m | 0.12% $ 346.4k | |
| Executive VP of Clinical Sciences & Project Management | 4.8yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Regulatory Affairs | 3.8yrs | geen gegevens | geen gegevens |
4.2yrs
Gemiddelde duur
61.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van AVIR wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 12.3yrs | US$5.93m | 7.09% $ 19.9m | |
| Independent Director | 4yrs | US$332.10k | 0.039% $ 110.4k | |
| Independent Director | 10.1yrs | US$324.60k | 0.098% $ 276.9k | |
| Lead Independent Director | 5.1yrs | US$357.10k | 0.96% $ 2.7m | |
| Independent Director | 9.9yrs | US$324.60k | 0.078% $ 218.5k | |
| Independent Director | 4.2yrs | US$327.10k | 0.067% $ 188.0k | |
| Independent Director | 3.4yrs | US$442.10k | 0.039% $ 110.4k |
5.1yrs
Gemiddelde duur
64yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van AVIR wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).